The Cooper Cos., a US medical device company, reached a $1.1 billion deal to acquire the ParaGard intrauterine contraceptive device business from Teva Pharmaceutical Industries. The transaction, which is part of Teva's planned divestment of its women's health unit, includes the device manufacturing facility in Buffalo, N.Y., and is expected to be completed by year-end.
Cooper to pay $1.1B for Teva's intrauterine contraceptive device business
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.